全文获取类型
收费全文 | 30375篇 |
免费 | 4446篇 |
国内免费 | 293篇 |
专业分类
耳鼻咽喉 | 919篇 |
儿科学 | 957篇 |
妇产科学 | 723篇 |
基础医学 | 3100篇 |
口腔科学 | 629篇 |
临床医学 | 3580篇 |
内科学 | 6173篇 |
皮肤病学 | 834篇 |
神经病学 | 3196篇 |
特种医学 | 1178篇 |
外科学 | 5731篇 |
综合类 | 665篇 |
现状与发展 | 3篇 |
一般理论 | 31篇 |
预防医学 | 2359篇 |
眼科学 | 921篇 |
药学 | 1487篇 |
中国医学 | 43篇 |
肿瘤学 | 2585篇 |
出版年
2023年 | 611篇 |
2022年 | 369篇 |
2021年 | 728篇 |
2020年 | 985篇 |
2019年 | 605篇 |
2018年 | 1133篇 |
2017年 | 923篇 |
2016年 | 1174篇 |
2015年 | 1142篇 |
2014年 | 1519篇 |
2013年 | 1946篇 |
2012年 | 1593篇 |
2011年 | 1436篇 |
2010年 | 1343篇 |
2009年 | 1516篇 |
2008年 | 1398篇 |
2007年 | 1284篇 |
2006年 | 1274篇 |
2005年 | 1223篇 |
2004年 | 1183篇 |
2003年 | 1078篇 |
2002年 | 1000篇 |
2001年 | 518篇 |
2000年 | 457篇 |
1999年 | 499篇 |
1998年 | 475篇 |
1997年 | 435篇 |
1996年 | 487篇 |
1995年 | 454篇 |
1994年 | 299篇 |
1993年 | 279篇 |
1992年 | 368篇 |
1991年 | 345篇 |
1990年 | 301篇 |
1989年 | 353篇 |
1988年 | 308篇 |
1987年 | 267篇 |
1986年 | 283篇 |
1985年 | 303篇 |
1984年 | 258篇 |
1983年 | 204篇 |
1982年 | 222篇 |
1981年 | 200篇 |
1980年 | 180篇 |
1979年 | 143篇 |
1978年 | 136篇 |
1977年 | 141篇 |
1976年 | 148篇 |
1975年 | 143篇 |
1974年 | 151篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
5.
6.
Dana Franzen-Klein Mark Jankowski Charlotte L. Roy Hoa Nguyen-Phuc Da Chen Lorin Neuman-Lee 《Journal of toxicology and environmental health. Part A》2020,83(2):45-65
ABSTRACTDomestic chickens (Gallus gallus domesticus) were exposed to imidacloprid by gavage once daily for 7 consecutive days at 0, 0.03, 0.34, 3.42, 10.25, and 15.5 mg/kg/day (n = 20 per group; 5 6-week-old males, 5 6-week-old females, 5 9-week-old males, and 5 9-week-old females). The severity and duration of neurobehavioral abnormalities were recorded. Components of the innate and adaptive immune system were assessed with 7 standard functional assays. Temporary neurobehavioral abnormalities were observed in a dose-dependent manner, including muscle tremors, ataxia, and depressed mentation. Based upon mean clinical severity scores, the no observed adverse effect level (NOAEL) was 3.42 mg/kg/day, and the lowest observed adverse effect level (LOAEL) was 10.25 mg/kg/day. The effective dose value for the presence of any neurobehavioral abnormalities in 50% of the test group (ED50) was 4.62 ± 0.98 mg/kg/day. The ED50 for an adjusted score that included both severity and duration of neurobehavioral abnormalities was 11.24 ± 9.33 mg/kg/day. These ED50 values are equivalent to a 1 kg bird ingesting 29 or 70 imidacloprid treated soybean seeds respectively. Immunotoxicity was not documented, possible causes include the assays were insensitive, relevant immune functions were not examined, or imidacloprid is not immunotoxic at this dosing schedule in this species. Neurobehavioral abnormalities were a more sensitive indicator of the sublethal effects of imidacloprid than immunotoxicity. 相似文献
7.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献8.
9.